Experts: FDA Should Not Amend Hormone Warnings Without Ad Comm

By Jessica Karins / August 6, 2025 at 3:26 PM

A group of women’s health professionals are urging FDA to avoid making changes to its boxed warnings on estrogen hormone therapy products without consulting an independent advisory committee, complaining a recent, less formal meeting on the topic included only supporters of hormone therapy.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.